Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
21 results
D3.295 - Comparing Real-World and AI-Enabled Market Research in Caregivers of Individuals with Peanut Allergy
D3.296 - Alpha-gal Syndrome with Concomitant Milk Sensitization in a Patient with Asthma and Allergic Rhinitis: A Case Report
D3.297 - De-labelling peanut allergy in a 19-year-old woman with detectable Ara h 2 sensitization: a real-life, exercise-augmented oral food challenge
D3.298 - The Good, the Bad and the Ugly : Mugwort, Mango, and Pineapple
D3.300 - Wheat tolerance induction protocol
D3.301 - Аллергия на белки коровьего молока у детей: сосредоточено на короткоцепочечных жирных кислотах
D3.302 - Sesame as an under-recognized allergen: storage protein sensitization underlying food-induced anaphylaxis in a young adult
D3.303 - Buckwheat Allergy in Bologna Metropolitan Area: Often Severe, Often Hidden
D3.304 - Real-Life Evaluation of the Egg Ladder in a Tertiary Pediatric Allergy Center in Turkey
D3.305 - Isolated IgE-Mediated Anaphylaxis to Pine Nut in an adult
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study
D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to
D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial
D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download